$AGIO

AGIOS PHARMACEUTICALS, INC.

Agios is a commercial-stage biopharmaceutical company developing and commercializing medicines for rare diseases, with a focus on hematology and cellular metabolism. Its approved products are mitapivat, marketed as PYRUKYND® for pyruvate kinase deficiency and as AQVESME™ for anemia in adults with alpha- or beta-thalassemia. The company is also developing mitapivat for additional conditions and advancing tebapivat for lower-risk myelodysplastic syndromes and sickle cell disease, AG-181 for phenylketonuria, and AG-236 for polycythemia vera. Agios sells its products directly in the United States and uses distribution partners to commercialize PYRUKYND® in the Gulf Cooperation Council region and in the European Economic Area, Switzerland, and the United Kingdom. It also provides access to PYRUKYND® through a global managed access program. Agios is headquartered in Cambridge, Massachusetts.

AlphAI earnings readThird Quarter 2026 · NOV 5Agios Reports Third Quarter 2026 Financial Results and Provides Business UpdateVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
0
1
—
$296K
Gheuens Sarah
100%
See all $AGIO insider activity →

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty

Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4M, up from $12.9M a year earlier, driven by strong AQVESME adoption. The company saw 177 new prescriptions, with 75% patient persistence. International revenue rose 74% to $6.6M. Agios prepares for a potential sickle cell launch, but faces FDA review extension and higher expenses. Q3 net loss narrowed to $65M from $103M YoY.

Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split

Dr. Reddy's (RDY) secured Brazil approval for generic semaglutide and tentative FDA approval for an HIV prevention shot. Lupin (LUPIN.NS) and Sun Pharma (SUNPHARMA.NS) received FDA approvals for generic Firdapse and Ilumya. Agios (AGIO) and Ultragenyx (RARE) announced significant job cuts. CVS (CVS) plans to split into two publicly traded companies. Teva (TEVA) expanded its biosimilars portfolio through a deal with Samsung Bioepis.

AGIO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning AGIO (AGIOS PHARMACEUTICALS, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent AGIO coverage spans financial news, earnings and regulation.

In the last 30 days, AGIO insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($296K). The most active reporter was Gheuens Sarah, Chief Medical Officer, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving AGIO

AlphAI scores every news story that mentions AGIO with an AI model for sentiment and relevance, and aggregates insider trades from AGIOS PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AGIO

Score

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty

Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4M, up from $12.9M a year earlier, driven by strong AQVESME adoption. The company saw 177 new prescriptions, with 75% patient persistence. International revenue rose 74% to $6.6M. Agios prepares for a potential sickle cell launch, but faces FDA review extension and higher expenses. Q3 net loss narrowed to $65M from $103M YoY.

Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split

Dr. Reddy's (RDY) secured Brazil approval for generic semaglutide and tentative FDA approval for an HIV prevention shot. Lupin (LUPIN.NS) and Sun Pharma (SUNPHARMA.NS) received FDA approvals for generic Firdapse and Ilumya. Agios (AGIO) and Ultragenyx (RARE) announced significant job cuts. CVS (CVS) plans to split into two publicly traded companies. Teva (TEVA) expanded its biosimilars portfolio through a deal with Samsung Bioepis.

Truist cuts Agios Pharma stock price target on SCD concerns

Truist Securities reduced its price target for Agios Pharmaceuticals (NASDAQ: AGIO) to $35 from $37, citing concerns about sickle cell disease. The stock is currently trading at $28.38, down 15.7% over the past week. Agios reported Q3 2026 earnings that missed expectations, but revenue exceeded estimates. The company announced a 35% reduction in R&D headcount, aiming for non-GAAP profitability in 2028.

$AGIOHighAI 8/10

Sickle cell data show hemoglobin gains lasting up to two years

Agios Pharmaceuticals (AGIO) announced new clinical data for its drugs mitapivat and AG-236, to be presented at ASH 2026. Mitapivat showed durable hemoglobin improvements for up to two years in sickle cell disease, with potential kidney and cardiac benefits. AG-236 data support every-six-month dosing in polycythemia vera. Agios will host an investor event on December 14, 2026.

The HCPFive: Top News for Healthcare Providers from the Week of 10/25

Vanda Pharmaceuticals reported positive phase 3 trial results for tradipitant in preventing GLP-1-induced vomiting, planning an FDA sNDA submission. Eli Lilly's retatrutide outperformed Ozempic in a type 2 diabetes trial. Agios Pharmaceuticals' mitapivat FDA review extended to February 2027. FDA approved Voceryq for recurrent respiratory papillomatosis.

The FDA added three months to its review after requesting information on possible safety measures for Agios' sickle cell drug.

Agios Pharmaceuticals (AGIO) announced a three-month extension in the FDA review of its sickle cell disease drug, mitapivat, due to additional information requested on safety measures. The new PDUFA goal date is February 1, 2027, pushed back from November 1, 2026. The FDA classified Agios' response as a major amendment, requiring further review. Mitapivat is currently approved for other anemias and is being evaluated under the FDA's accelerated approval pathway.

Related tickers